Sign In
Buy XNCR
$20.21
-1.28 (-5.96%)
At Close: Jul 31, 2026
Xencor (XNCR) Loses 12.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:18am, Wednesday, 30'th Jun 2021
Xencor (XNCR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea
4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness
11:17am, Monday, 21'st Jun 2021
4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and aut
Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q1 2021 Results - Earnings Call Transcript
06:42pm, Saturday, 08'th May 2021
Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q1 2021 Results - Earnings Call Transcript
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
06:25pm, Wednesday, 05'th May 2021
Xencor (XNCR) delivered earnings and revenue surprises of 94.81% and 160.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and aut
Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics
05:01am, Thursday, 25'th Feb 2021
MONROVIA, Calif. & LOS ANGELES--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of c
Xencor Inc (XNCR) CEO Bassil Dahiyat on Q4 2020 Results - Earnings Call Transcript
12:21am, Wednesday, 24'th Feb 2021
Xencor Inc (XNCR) CEO Bassil Dahiyat on Q4 2020 Results - Earnings Call Transcript
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
06:15pm, Tuesday, 23'rd Feb 2021
Xencor (XNCR) delivered earnings and revenue surprises of 55.56% and 97.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Adagene Readies Plan For $132 Million U.S. IPO
05:13pm, Thursday, 04'th Feb 2021
Adagene Readies Plan For $132 Million U.S. IPO
Xencor (XNCR) Inks Deal for Novel Antibody Therapies in Cancer
09:47am, Thursday, 07'th Jan 2021
Xencor (XNCR) signs a strategic research collaboration deal with MD Anderson Cancer Center to develop and commercialize T Cell-engaging bispecific antibodies for treating cancer.
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease
Xencor Presents Updated Data from the Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
05:00pm, Sunday, 06'th Dec 2020
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease
Xencor Inc (XNCR) CEO Bassil Dahiyat on Q3 2020 Results - Earnings Call Transcript
10:01am, Sunday, 08'th Nov 2020
Xencor Inc (XNCR) CEO Bassil Dahiyat on Q3 2020 Results - Earnings Call Transcript
Xencor to Present Data from Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
10:15am, Wednesday, 04'th Nov 2020
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease
